High Throughput Proteomics Systems for Accelerated Profiling of Putative Plasma Biomarkers
At a Glance
- Status: Completed Consortium
- Year Launched: 2008
- Initiating Organization: European Commission
- Initiator Type: Government
- Disease focus:
- Location: Europe
The PROACTIVE consortium will through research and innovation develop the multiplexed proximity ligation assay into a high throughput protein detection and quantification technology along with novel data management and analysis tools. Hundreds of putative biomarkers of the plasma proteome can then be assayed with high sensitivity in minute sample volumes, far surpassing any current capabilities. This consortium combines three SMEs across Europe with synergistic competences in technology development, reagent manufacturing, and software development for data management and analysis. Together with clinical cancer scientists, biostatisticians, and diagnostics industry, these high capacity tools will be evaluated in pilot projects for cancer biomarkers using bio-banked samples.
At the conclusion of this collaborative project, the research and innovation conducted within the consortium will enable the partners to position themselves at the very forefront of high-throughput biomarker research strengthening their competitiveness in the international arena.
The goal of the PROACTIVE consortium was to develop a validated and fully operational high throughput targeted proteomics pipeline for analysis of human blood samples capable of detecting very large sets of putative cancer biomarkers.
Structure & Governance
This consortium is the project of CORDIS (Community Research and Development Information Service), which is a program of the European Commission.
Funded by the European Commission
Work produced by the consortium is owned by the European Commission
Implementation of the PROACTIVE system on a cohort of patients with colorectal cancer led to the identification of proteins specific for the early stages of the disease. These constitute putative diagnostic biomarker candidates and subsequent validation will determine their future incorporation into a plasma biomarker service.
The consortium’s summary report can be found here
Points of Contact
Olink Bioscience AB
CHEMISTRY BMC - BOX 599
751 24 UPPSALA
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative contact : Simon Fredriksson
Tel.: +46 (0)18 - 444 39 84
Fax: -+46 (0)18 - 50 93 00
Sponsors & Partners
Innova Biosciences Limited
Integromics SL ITG
Fujirebio Diagnostics AB
Olink Bioscience AB